Longeveron(LGVN.US)

Last Updated 19:00:00 ET
longbridge loading

Longeveron Q1 2026 Earnings Call: Complete Transcript

benzinga_article·
US
LGVN
-0.41%
US
BBH
+0.68%
US
LABD
+2.41%
benzinga_article·
US
LGVN
-0.41%
US
BBH
+0.68%
US
LABD
+2.41%

Longeveron | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 398 K

Earnings Watch·
US
LGVN
-0.41%
Earnings Watch·
US
LGVN
-0.41%

Longeveron | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 398 K

Earnings Watch·
US
LGVN
-0.41%
Earnings Watch·
US
LGVN
-0.41%

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga_article·
US
ZYBT
-5.64%
US
APUS
-4.70%
US
LGVN
-0.41%
benzinga_article·
US
ZYBT
-5.64%
US
APUS
-4.70%
US
LGVN
-0.41%

Longeveron Holds Constructive FDA Meeting; ELPIS II Topline Data Expected August 2026

nasdaq·
US
LGVN
-0.41%
US
FBT
+0.54%
US
SBIO
-1.24%
nasdaq·
US
LGVN
-0.41%
US
FBT
+0.54%
US
SBIO
-1.24%

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) | LGVN Stock News

StockTitan·
US
LGVN
-0.41%
US
BBH
+0.68%
US
BIB
+0.05%
StockTitan·
US
LGVN
-0.41%
US
BBH
+0.68%
US
BIB
+0.05%
© 2026 Longbridge｜Disclaimer